1. Home
  2. PDSB vs MCRB Comparison

PDSB vs MCRB Comparison

Compare PDSB & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PDS Biotechnology Corporation

PDSB

PDS Biotechnology Corporation

HOLD

Current Price

$0.88

Market Cap

62.0M

Sector

Health Care

ML Signal

HOLD

Logo Seres Therapeutics Inc.

MCRB

Seres Therapeutics Inc.

HOLD

Current Price

$7.08

Market Cap

71.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDSB
MCRB
Founded
2005
2010
Country
United States
United States
Employees
10
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
62.0M
71.0M
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
PDSB
MCRB
Price
$0.88
$7.08
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
$9.00
$14.00
AVG Volume (30 Days)
858.3K
84.9K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
28.16
N/A
EPS
N/A
N/A
Revenue
N/A
$789,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$5.31
52 Week High
$1.55
$29.98

Technical Indicators

Market Signals
Indicator
PDSB
MCRB
Relative Strength Index (RSI) 40.70 51.83
Support Level $0.88 $6.56
Resistance Level $1.12 $9.53
Average True Range (ATR) 0.10 0.71
MACD -0.02 0.13
Stochastic Oscillator 8.76 75.66

Price Performance

Historical Comparison
PDSB
MCRB

About PDSB PDS Biotechnology Corporation

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.

Share on Social Networks: